We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BioAge Labs Inc (BIOA) USD0.00001

Sell:$6.16 Buy:$6.21 Change: $0.97 (18.76%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$6.16
Buy:$6.21
Change: $0.97 (18.76%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$6.16
Buy:$6.21
Change: $0.97 (18.76%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

Contact details

Address:
1445A South 50Th Street
RICHMOND
94804
United States
Telephone:
+1 (510) 8061445
Website:
https://bioagelabs.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIOA
ISIN:
US09077V1008
Market cap:
$154.15 million
Shares in issue:
35.85 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kristen Fortney
    President, Chief Executive Officer, Director
  • Dov Goldstein
    Chief Financial Officer
  • Eric Morgen
    Chief Operating Officer, Director
  • Paul Rubin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.